EMD-50066

Single-particle
3.3 Å
EMD-50066 Deposition: 10/04/2024
Map released: 29/01/2025
Last modified: 29/01/2025
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-50066

Poliovirus type 1 (strain Mahoney) expanded conformation stabilised virus-like particle (PV1 SC6b) from a yeast expression system.

EMD-50066

Single-particle
3.3 Å
EMD-50066 Deposition: 10/04/2024
Map released: 29/01/2025
Last modified: 29/01/2025
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Human poliovirus 1 Mahoney
Sample: Human poliovirus 1 Mahoney
Fitted models: 9ez0

Deposition Authors: Bahar MW , Sherry L , Stonehouse NJ , Rowlands DJ , Fry EE , Stuart DI
Recombinant expression systems for production of stabilised virus-like particles as next-generation polio vaccines.
PUBMED: 39827284
DOI: doi:10.1038/s41467-025-56118-z
ISSN: 2041-1723
Abstract:
Polioviruses have caused crippling disease in humans for centuries, prior to the successful development of vaccines in the mid-1900's, which dramatically reduced disease prevalence. Continued use of these vaccines, however, threatens ultimate disease eradication and achievement of a polio-free world. Virus-like particles (VLPs) that lack a viral genome represent a safer potential vaccine, although they require particle stabilization. Using our previously established genetic techniques to stabilize the structural capsid proteins, we demonstrate production of poliovirus VLPs of all three serotypes, from four different recombinant expression systems. We compare the antigenicity, thermostability and immunogenicity of these stabilized VLPs against the current inactivated polio vaccine, demonstrating equivalent or superior immunogenicity in female Wistar rats. Structural analyses of these recombinant VLPs provide a rational understanding of the stabilizing mutations and the role of potential excipients. Collectively, we have established these poliovirus stabilized VLPs as viable next-generation vaccine candidates for the future.